6 completed. 6 Phase 1.
By phase and status
Follow JNJ-54175446: new trials by email Literature Review of JNJ-54175446 trials Research Report on JNJ-54175446
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739
JNJ-54175446, 18F-JNJ-64413739 - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 16 | 2017-03-24 | 2025-04-27 |
A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects
JNJ-54175446 150 mg, JNJ-54175446 600 mg, Midazolam 2 mg - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 16 | 2017-03-14 | 2017-06-08 |
A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder
JNJ-54175446, 600 mg, JNJ-54175446, 150 mg, Placebo - Depressive Disorder, Major | Phase 1 | Completed | Janssen Research & Development, LLC | 70 | 2016-10-17 | 2025-04-27 |
A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants
JNJ-54175446 (capsule), JNJ-54175446 (suspension) - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 32 | 2016-10-01 | 2017-02-16 |
A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma
JNJ-54175446, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 25 | 2016-09-01 | 2025-02-03 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants
JNJ-54175446, Minocycline, JNJ 54175446 Matching Placebo - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 76 | 2015-08-01 | 2025-02-03 |
Conditions studied
Depressive Disorder, Major (1)
Sponsors
Janssen Research & Development, LLC (4) · Janssen-Cilag International NV (2)
Countries
Belgium (3) · Netherlands (2) · Germany (1) · United States (1)
Results publications
PMID 35774109
NIH funding
2016 (4), 2015 (1)